ArticleBMC geriatrics2025
Development and psychometric testing of symptom severity scale in older patients with cardiometabolic multimorbidity.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundGiven the high prevalence of multiple cardiometabolic disorders in the older population and their negative impact on quality of life, assessing symptom burden is of critical importance. No assessment tool is available to holistically measure the severity of common symptoms in cardiometabolic diseases. This study aimed to develop the "Symptom Severity Scale in Patients with Cardiometabolic Multimorbidity (SSS-CM)" and to perform psychometric testing in the Turkish older population.
methodsThis methodological study was conducted between August and November 2024 with patients (n = 388) aged ≥ 65 years with at least two cardiometabolic diseases (coronary heart disease, hypertension, diabetes mellitus, stroke, and dyslipidemia) who were followed up in the internal medicine, cardiology, and neurology clinics of a training and research hospital. Data was collected using the Patient Information Form, the SSS-CM, and the EQ-5D-3 L scale. The validity and reliability of the scale were tested using exploratory and confirmatory factor analyses, Cronbach's alpha analysis, and Pearson correlation analysis.
resultsThe exploratory factor analysis determined that the scale had a single-factor structure explaining 65.753% of the total variance, and the factor loads ranged between 0.658 and 0.898. In confirmatory factor analysis, χ2/df = 1.739. Cronbach's alpha internal consistency coefficient was found to be 0.978. Pearson correlation analysis showed a significant negative correlation between symptom severity and overall quality of life.
conclusionsThe SSS-CM is a valid and reliable measurement tool for assessing symptom severity in cardiometabolic older patients with complex care and treatment needs. This scale could contribute to assessing the effectiveness of symptom management interventions to alleviate symptoms and improve the quality of life among the older population. However, the findings should be interpreted with caution due to the purposive sampling from a single center setting in Turkey, which may limit the generalizability across different populations and healthcare systems. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.